+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-11-17Number of Pages: 176

Scleroderma Diagnostics and Therapeutics Market (Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors; Indication - Localized and Systemic; Diagnostic Test Type - Skin Biopsy, Imaging Techniques, Blood Test, Electrocardiogram and Echocardiogram, and Pulmonary Function Tests) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Scleroderma Diagnostics and Therapeutics Market: Snapshot

The scleroderma therapeutics and diagnostics market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to the increasing focus globally on treatment of orphan diseases. The lack of approved drugs in the market makes it a highly opportune condition for players to convert their innovative drug ideas into successful treatment methods for this rare chronic inflammatory disease.

According to Transparency Market Research, the global scleroderma diagnostics and therapeutics market was valued at US$1,633.5 mn in 2015 and is projected to expand at a CAGR of 9.7% from 2016 to 2024 to reach US$3,663.7 mn by 2024.

scleroderma diagnostics therapeutics market

 

Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market, the treatment of scleroderma is challenging for a physician, since no two patients are alike in the progress of their disease. Thus, a host of different drugs are prescribed to every patient, depending on the extent, severity and nature of their symptoms.

It has been observed that patient consumption patterns in the global scleroderma diagnostics and therapeutics market are inclined towards immunosuppressive agents, which have shown to provide relief against several symptoms in both systemic and localized scleroderma cases. Moreover, of the very few treatments identified to efficaciously modify the course of scleroderma, physicians often recommend immunosuppressive agents to manage the most common symptoms of the disease. The segment, as a result, accounts for the dominant share in the global market.

Prostacyclin analogues have been found to have a potent effect in treating systemic scleroderma patients who suffer from pulmonary arterial hypertension. However, these drugs are expensive and thus, even though a smaller sub-set of patients is administered with these agents, their market value is high. This segment grabbed over 8.0% share of the global scleroderma therapeutics market in 2015, and is anticipated to slightly decline by 2024 owing to availability of cheaper alternatives within this segment.

Developed Regions to Continue to Command Dominance

Owing to better diagnostic and treatment rates, in part due to proactive awareness-raising initiatives by various foundations, have aided North America and Europe gain the predominant share in the global scleroderma diagnostics and therapeutics market. North America accounted for a share of nearly 34.0% while Europe held nearly 30% of the global scleroderma therapeutics market in 2015. This is attributed to presence of renowned pharmaceutical companies, research organizations, and institutes in the regions, which are focused on finding a standard treatment for the condition.

The North America and Europe markets for scleroderma diagnostics and therapeutics are expected to retain their dominance in the global scleroderma diagnostics and therapeutics market throughout the forecast period, exhibiting CAGRs of 11.2% and 10.9%, respectively, over the period between 2016 and 2024. The ongoing cutting-edge research pertaining to scleroderma will aid the growth of a niche scleroderma diagnostics and therapeutics market in these regions.

Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2015. The Asia Pacific market will also retain its position in the global market over the forecast period, with factors such as large population and high unmet needs working in favor of market expansion in the region.

Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.

Global Scleroderma Diagnostics and Therapeutics Market: Overview

Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and “derma,” meaning skin. Thus, scleroderma literally translates to “hard skin.” Scleroderma is a group of diseases that involves the abnormal growth of connective tissue, which supports the skin and internal organs. In some forms of scleroderma, the extent of the abnormality of the disease is limited to hard, tight skin. In certain other forms, however, the predicament is worse, where the impact goes much deeper, affecting blood vessels and internal organs, such as the heart, lungs, and kidneys. Scleroderma has no known cure and is a chronic condition, in which patients are affected for life. Localized scleroderma patients, however, with mild symptoms, often see the skin patches disappear on their own in a few years post-onset.

Global Scleroderma Diagnostics and Therapeutics Market: Scope of the Report

This report on the global scleroderma diagnostics and therapeutics market analyzes the current and future prospects of the market. The markets of diagnostics and therapeutics are independently analyzed as two separate markets within the report. The market for scleroderma therapeutics is segmented based on drug class, indication and region, while the market for scleroderma diagnostics is segmented on the basis of test type and region. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as new drug launches, drugs in the pipeline, industry-institute collaborations in research for finding a pertinent cure, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the global scleroderma diagnostics and therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Scleroderma Diagnostics and Therapeutics Market: Segmentation

Based on indication, the global scleroderma diagnostics and therapeutics market has been segmented into localized and systemic scleroderma. Localized scleroderma affects only the skin, and in certain patients, the underlying muscle, however, systemic scleroderma (also known as systemic sclerosis) is much severe and affects the internal organs as well.

The major drug classes for treatment of scleroderma include Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, and Others. The others segment includes the drug classes of analgesics, proton pump inhibitors, prokinetic agents, H2 blockers and ACE inhibitors etc. which are used in symptomatic relief to the patient. Immunosuppressive agents and low dose corticosteroids are the most commonly prescribed agents to treat scleroderma.

Based on test type, the diagnostics market has been segmented into skin biopsy, imaging techniques, blood test, electrocardiogram and echocardiogram, and pulmonary function tests. Diagnosis of the disease is based on physician’s assessment of patients’ medical history and clinical manifestations. In addition, tests and procedures are undertaken to validate the clinical diagnosis and exclude alternative diagnoses, and later for assessment of organ involvement and monitoring of disease progression.

Global Scleroderma Diagnostics and Therapeutics Market: Geographical and Competitive Dynamics

Geographically, the global scleroderma diagnostics and therapeutics market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries for the scleroderma therapeutics market These include the U.S., Canada, the U.K., Germany, France,  China, Japan, India, Brazil, Mexico, the UAE, and South Africa. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the radiodermatitis market.

The report also profiles major players in the scleroderma therapeutics and diagnostics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Cumberland Pharmaceuticals Inc, Gilead Sciences, Inc., Pfizer, Inc., and Sanofi.

The global scleroderma therapeutics and diagnostics market has been segmented as follows:

Global Scleroderma Therapeutics Market, by Drug Class

  • Corticosteroids
  • Immunosuppressive Agents 
  • Endothelin Receptor Agonists
  • Calcium Channel Blockers
  • PDE-5 Inhibitors
  • Chelating Agents
  • Prostacyclin Analogues
  • Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)

Global Scleroderma Therapeutics Market, by Indication

  • Localized
  • Systemic

Global Scleroderma Diagnostics Market, by Test Type

  • Skin Biopsy
  • Imaging Techniques
  • Blood Tests
  • Electrocardiogram and Echocardiogram
  • Pulmonary Function Tests

Global Scleroderma Diagnostics and Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • Rest of APAC
  • Europe
    • France
    • Germany
    • U.K.
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • UAE
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top